Ni Jinsong, Ouyang Hui, Seto Carmai, Sakuma Takeo, Ellis Robert, Rowe Josh, Acheampong Andrew, Welty Devin, Szekely-Klepser Gabriella
RD2-2B, Department of Drug Safety Evaluation, Allergan, 2525 Dupont Drive, Irvine, CA 92612, USA. ni_jinsong@ allergan.com
Bioanalysis. 2010 Mar;2(3):407-19. doi: 10.4155/bio.10.10.
The objective of this study was to evaluate the sensitivity requirement for LC-MS/MS as an analytical tool to characterize metabolites in plasma and urine at microdoses in rats and to investigate proportionality of metabolite exposure from a microdose of 1.67 µg/kg to a high dose of 5000 µg/kg for atorvastatin, ofloxacin, omeprazole and tamoxifen.
Only the glucuronide metabolite of ofloxacin, the hydroxylation metabolite of omeprazole and the hydration metabolite of tamoxifen were characterized in rat plasma at microdose by LC-MS/MS. The exposure of detected metabolites of omeprazole and tamoxifen appeared to increase in a nonproportional manner with increasing doses. Exposure of ortho- and para-hydroxyatorvastatin, but not atorvastatin and lactone, increased proportionally with increasing doses.
LC-MS/MS has demonstrated its usefulness for detecting and characterizing the major metabolites in plasma and urine at microdosing levels in rats. The exposure of metabolites at microdose could not simply be used to predict their exposure at higher doses.
本研究的目的是评估液相色谱-串联质谱(LC-MS/MS)作为一种分析工具在大鼠微剂量下表征血浆和尿液中代谢物的灵敏度要求,并研究阿托伐他汀、氧氟沙星、奥美拉唑和他莫昔芬从1.67 µg/kg的微剂量到5000 µg/kg的高剂量时代谢物暴露的比例关系。
通过LC-MS/MS仅在大鼠血浆微剂量下鉴定出氧氟沙星的葡萄糖醛酸代谢物、奥美拉唑的羟基化代谢物和他莫昔芬的水合代谢物。奥美拉唑和他莫昔芬检测到的代谢物暴露似乎随着剂量增加而非比例增加。邻羟基和对羟基阿托伐他汀的暴露随剂量增加成比例增加,但阿托伐他汀和内酯的暴露并非如此。
LC-MS/MS已证明其在检测和表征大鼠微剂量水平下血浆和尿液中的主要代谢物方面的有用性。微剂量下代谢物的暴露不能简单地用于预测其在更高剂量下的暴露。